Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

12Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-type lung adenocarcinoma. Methods: After extensive literature review, a 5-member scientific committee generated 33 statements in 4 domains: general aspects (n = 4); post-durvalumab in locally advanced disease (n = 6); post-first-line immunotherapy ± chemotherapy in advanced/metastatic disease (n = 11); and post-first-line platinum-based chemotherapy in advanced/metastatic disease (n = 12). A panel of 26 lung cancer experts completed 2 Delphi iterations through an online platform rating their degree of agreement/disagreement (first-round scale 1–5 and second-round scale 1–4, 1 = strongly disagree, 4/5 = strongly agree) for each statement. Second-round consensus: ≥ 70% of responses were in categories 1/2 (disagreement) or 3/4 (agreement). Results: Consensus was reached for 2/33 statements in the first Delphi round and in 29/31 statements in the second round. Important variables informing treatment at disease progression with an immunotherapy-based treatment include: disease aggressiveness, previous treatment, accumulated toxicity, progression-free interval, PD-L1 expression, and tumour mutational burden. A platinum-based chemotherapy should follow a first-line immunotherapy treatment without chemotherapy. Treatment with docetaxel + nintedanib may be appropriate post-durvalumab in refractory patients or following progression to first-line chemotherapy + immunotherapy, or second-line chemotherapy after first-line immunotherapy, or first-line chemotherapy in some patients with low/negative PD-L1 expression, or second-line immunotherapy after first-line chemotherapy. Conclusions: To support decision making following progression to immunotherapy-based treatment in patients with advanced wild-type lung adenocarcinoma, a consensus document has been developed.

References Powered by Scopus

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

8395Citations
N/AReaders
Get full text

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

8242Citations
N/AReaders
Get full text

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

5698Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

40Citations
N/AReaders
Get full text

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

24Citations
N/AReaders
Get full text

Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Isla, D., de Castro, J., García-Campelo, R., Lianes, P., Felip, E., Garrido, P., … Trigo, J. M. (2020). Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clinical and Translational Oncology, 22(5), 759–771. https://doi.org/10.1007/s12094-019-02191-y

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

57%

Researcher 2

29%

Professor / Associate Prof. 1

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

64%

Nursing and Health Professions 2

18%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Engineering 1

9%

Save time finding and organizing research with Mendeley

Sign up for free